UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Impact of the Early Benefit Assessment on A Pharmaceutical's Real Consumption in Germany

Value in health, 2014-11, Vol.17 (7), p.A416-A416

2014

Link zum Volltext

Verfügbarkeit prüfen

Inpatient Case-Related Treatment Costs For Different Cardiovascular Diseases In Germany

Value in health, 2014-11, Vol.17 (7), p.A492-A492

2014

Link zum Volltext

Verfügbarkeit prüfen

PRM4 Assessment of Immunosuppressive Therapies for Renal Transplantation - Criteria Considered for Evaluation by the EMA, European HTA Agencies and the German IQWiG

Value in health, 2012-11, Vol.15 (7), p.A460-A460

2012

Link zum Volltext

Verfügbarkeit prüfen

Different persistence on initial basal supported oral therapy in Type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany

International journal of clinical pharmacology and therapeutics, 2010-11, Vol.48 (11), p.761

2010

Link zum Volltext

Verfügbarkeit prüfen

PCN101 - Annual Costs of Best Supportive Care for Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) in Germany

Value in health, 2017-10, Vol.20 (9), p.A430-A430

2017

Link zum Volltext

Verfügbarkeit prüfen

Annual Costs of Best Supportive Care for Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) in Germany

Value in health, 2017-10, Vol.20 (9), p.A430

2017

Link zum Volltext

Verfügbarkeit prüfen

PNS144 HOW THE RESULTS OF THE AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY HAVE DEVELOPED OVER TIME

Value in health, 2019-11, Vol.22, p.S785-S785

2019

Link zum Volltext

Verfügbarkeit prüfen

Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics

Value in health, 2016-11, Vol.19 (7), p.A680-A681

2016

Link zum Volltext

Verfügbarkeit prüfen

PDB88 - Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics

Value in health, 2016-11, Vol.19 (7), p.A680-A681

2016

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing

Journal of cancer research and clinical oncology, 2004-04, Vol.130 (4), p.235-241

2004

Link zum Volltext

Verfügbarkeit prüfen

Is The Proof of an Additional Benefit under amnog in Germany More Difficult for Certain Drugs than for Other Ones?

Value in health, 2015-11, Vol.18 (7), p.A523-A523

2015

Link zum Volltext

Verfügbarkeit prüfen

PHP53 - Is The Proof of an Additional Benefit under amnog in Germany More Difficult for Certain Drugs than for Other Ones?

Value in health, 2015-11, Vol.18 (7), p.A523-A523

2015

Link zum Volltext

Verfügbarkeit prüfen

PCV112 - Inpatient Case-Related Treatment Costs For Different Cardiovascular Diseases In Germany

Value in health, 2014-11, Vol.17 (7), p.A492-A492

2014

Link zum Volltext

Verfügbarkeit prüfen

PHP71 - Impact of the Early Benefit Assessment on A Pharmaceutical's Real Consumption in Germany

Value in health, 2014-11, Vol.17 (7), p.A416-A416

2014

Link zum Volltext

Verfügbarkeit prüfen

PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY–A COST-SAVING SECOND-LINE TREATMENT OPTION?

Value in health, 2006-11, Vol.9 (6), p.A278-A278

2006

Link zum Volltext

Verfügbarkeit prüfen

PDB55 COMPARISON OF RESOURCE USE AND COSTS IN TYPE 1 DIABETES PATIENTS TREATED WITH DIFFERENT LONG ACTING INSULINS IN A BASAL-BOLUS REGIMEN IN GERMANY

Value in health, 2010, Vol.13 (7), p.A294-A294

2010

Link zum Volltext

Verfügbarkeit prüfen

PDB7 PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS UNDER REAL-LIFE CONDITIONS IN GERMANY

Value in health, 2010, Vol.13 (7), p.A284-A284

2010

Link zum Volltext

Verfügbarkeit prüfen

PDB16 INSULIN GLARGINE IS ASSOCIATED WITH A LOWER INCIDENCE OF DIABETIC FOOT SYNDROME AND MACROVASCULAR COMPLICATIONS COMPARED TO NPH INSULIN IN TYPE 2 DIABETICS UNDER GERMAN REAL-LIFE CONDITIONS

Value in health, 2010, Vol.13 (7), p.A286-A286

2010

Link zum Volltext

Verfügbarkeit prüfen

PDB43 ADDING INSULIN GLARGINE TO ORALTHERAPY IN PATIENTS WITHTYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN

Value in health, 2008, Vol.11 (6), p.A509-A510

2008

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Strong Opioids Focussing on the Long-Term Effects of Opioid-Related Fractures: A Model Approach

The European journal of health economics, 2009-07, Vol.10 (3), p.309-321

2009

Link zum Volltext

Verfügbarkeit prüfen

PDB34 LOWER LONG-TERM COSTS IN GERMAN TYPE-2-DIABETICS STARTING A BASAL SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE COMPARED TO NPH-INSULIN

Value in health, 2009, Vol.12 (7), p.A407-A408

2009

Link zum Volltext

Verfügbarkeit prüfen

PDB10 DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY (BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT REGIMENS IN TYPE-2-DIABETICS

Value in health, 2009, Vol.12 (7), p.A403-A403

2009

Link zum Volltext

Verfügbarkeit prüfen

PPN3 ESTIMATED COSTS ASSOCIATED WITH DIFFERENT FRACTURE RISKS RELATED TO OPIOID TREATMENT IN GERMANY

Value in health, 2007, Vol.10 (3), p.A172-A172

2007

Link zum Volltext

Verfügbarkeit prüfen

PCV31 LONG-TERM COST-EFFECTIVENESS OF RIMONABANT IN GERMANY

Value in health, 2007, Vol.10 (6), p.A414-A415

2007

Link zum Volltext

Verfügbarkeit prüfen

PSY16 COST-EFFECTIVENESS OFTRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY— A MODEL APPROACH

Value in health, 2008, Vol.11 (3), p.A157-A157

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Impact of the Early Benefit Assessment on A Pharmaceutical's Real Consumption in Germany

Inpatient Case-Related Treatment Costs For Different Cardiovascular Diseases In Germany

PRM4 Assessment of Immunosuppressive Therapies for Renal Transplantation - Criteria Considered for Evaluation by the EMA, European HTA Agencies and the German IQWiG

Different persistence on initial basal supported oral therapy in Type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany

PCN101 - Annual Costs of Best Supportive Care for Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) in Germany

Annual Costs of Best Supportive Care for Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) in Germany

PNS144 HOW THE RESULTS OF THE AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY HAVE DEVELOPED OVER TIME

Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics

PDB88 - Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics

Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing

Is The Proof of an Additional Benefit under amnog in Germany More Difficult for Certain Drugs than for Other Ones?

PHP53 - Is The Proof of an Additional Benefit under amnog in Germany More Difficult for Certain Drugs than for Other Ones?

PCV112 - Inpatient Case-Related Treatment Costs For Different Cardiovascular Diseases In Germany

PHP71 - Impact of the Early Benefit Assessment on A Pharmaceutical's Real Consumption in Germany

PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY–A COST-SAVING SECOND-LINE TREATMENT OPTION?

PDB55 COMPARISON OF RESOURCE USE AND COSTS IN TYPE 1 DIABETES PATIENTS TREATED WITH DIFFERENT LONG ACTING INSULINS IN A BASAL-BOLUS REGIMEN IN GERMANY

PDB7 PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS UNDER REAL-LIFE CONDITIONS IN GERMANY

PDB16 INSULIN GLARGINE IS ASSOCIATED WITH A LOWER INCIDENCE OF DIABETIC FOOT SYNDROME AND MACROVASCULAR COMPLICATIONS COMPARED TO NPH INSULIN IN TYPE 2 DIABETICS UNDER GERMAN REAL-LIFE CONDITIONS

PDB43 ADDING INSULIN GLARGINE TO ORALTHERAPY IN PATIENTS WITHTYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN

Cost-Effectiveness of Strong Opioids Focussing on the Long-Term Effects of Opioid-Related Fractures: A Model Approach

PDB34 LOWER LONG-TERM COSTS IN GERMAN TYPE-2-DIABETICS STARTING A BASAL SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE COMPARED TO NPH-INSULIN

PDB10 DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY (BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT REGIMENS IN TYPE-2-DIABETICS

PPN3 ESTIMATED COSTS ASSOCIATED WITH DIFFERENT FRACTURE RISKS RELATED TO OPIOID TREATMENT IN GERMANY

PCV31 LONG-TERM COST-EFFECTIVENESS OF RIMONABANT IN GERMANY

PSY16 COST-EFFECTIVENESS OFTRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY— A MODEL APPROACH

Suchergebnisse filtern